MedPAC Adviser Worries Part D Lacks Tools To Manage After-Effects Of IRA Measures

By Gabrielle Wanneh / January 19, 2023 at 2:04 PM
Redesigning the Medicare Part D drug benefit is expected to boost incentives for prescription drug plan sponsors to manage their spending, according to staff for the Medicare Payment Advisory Commission (MedPAC), but one commissioner worries that Part D plans lack the tools needed to manage the benefit once the redesign takes effect in 2025, especially when it comes to specialty drug spending and the six protected classes of drugs Medicare must cover. Staff analysts presented a status report on Part...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.